-+ 0.00%
-+ 0.00%
-+ 0.00%
Reported Friday, NeuroSense Therapeutics Receives Dual Nasdaq Non-Compliance Notices For Minimum Bid Price And $35M Market Value Requirements, Given Until September 29, 2026
Share
Listen to the news
  • Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq
  • Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements
  • The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending